Abstract
Three strains of human esophageal carcinoma xenografts established in our institution were tested against combination chemotherapy in vivo and in vitro. TS-1 plus cisplatin (CDDP) was shown to be an effective combination against two carcinoma strains of moderately-differentiated type. Determination of the thymidylate synthase (TS) demonstrated a higher inhibition of the enzyme by adding CDDP to 5-FU, suggesting biochemical modulation. The remaining strain of poorly-differentiated type was resistant to the combination and an attempt was made to add docetaxel (DTX) to show that the three-drug combination was effective against the strain. Combination chemotherapy including TS-1 and CDDP thus appears to be useful treatment choice for esophageal carcinoma.
MeSH terms
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
-
Cisplatin / administration & dosage
-
Cisplatin / pharmacology
-
Docetaxel
-
Drug Combinations
-
Drug Synergism
-
Esophageal Neoplasms / drug therapy*
-
Esophageal Neoplasms / pathology*
-
Fluorouracil / administration & dosage
-
Fluorouracil / pharmacology
-
Humans
-
Mice
-
Mice, Nude
-
Neoplasm Transplantation
-
Oxonic Acid / administration & dosage
-
Oxonic Acid / pharmacology
-
Pyridines / administration & dosage
-
Pyridines / pharmacology
-
Succinate Dehydrogenase / antagonists & inhibitors
-
Taxoids / administration & dosage
-
Taxoids / pharmacology
-
Tegafur / administration & dosage
-
Tegafur / pharmacology
-
Thymidylate Synthase / antagonists & inhibitors
-
Tumor Cells, Cultured / drug effects
Substances
-
Drug Combinations
-
Pyridines
-
Taxoids
-
S 1 (combination)
-
Tegafur
-
Docetaxel
-
Oxonic Acid
-
Succinate Dehydrogenase
-
Thymidylate Synthase
-
Cisplatin
-
Fluorouracil